(SANTA CLARA, CALIF., NOV. 18, 2015) — Crown Bioscience, A Global Drug Discovery And Development Services Company Providing Translational Platforms To Advance Oncology And Metabolic Disease Research, Now Provides A Comprehensive Immuno-Oncology Translational Research Platform.
“Crown’s suite of in vitro and in vivo immuno-oncology assays employing translational experimental models help inform and accelerate the development of cancer immunotherapies and move the best candidates forward to clinical trials,” said Jean-Pierre Wery, Ph.D., president of Crown Bioscience.
Crown’s in vitro immuno-oncology assays, including immunophenotyping and immuno-functional assays, help scientists validate immuno-oncology targets, screen for immuno-modulating agents, understand mechanisms of actions and identify biomarkers. With one of the world’s largest collections of validated in vivo syngeneic cell line models, as well as primary allografts of tumors, Crown helps scientists evaluate and understand novel anticancer compounds.
“In addition, we provide the unique capability to combine image-guided micro-irradiation with our syngeneic models to explore combination therapeutic strategies involving targeted irradiation with immunotherapies,” Wery added.
Crown also provides various humanized immuno-oncology in vivo models, including theMiXeno™ platform of transient human immunity by mixing human peripheral blood mononucleated cells (PBMC) with xenograft models for testing human biological-based immunotherapeutics for cancers, providing a simple, cost-effective alternative to full hematopoietic stem cell reconstitution. Crown’s other humanized immuno-oncology technologies under development include HuGEMM with knocked-in human checkpoint targets, e.g., huPD1 and huCTLA4, into immunocompetent models and PDX in human hematopoietic stem reconstituted models, both of which will be extremely valuable in evaluating human biologicals for immunotherapies.
Crown’s industry-leading translational models include a unique collection of HuPrime®cancer models available through its HuBase™ annotated database for researchers to predict and guide clinical development. Crown’s proprietary genetic signature technology (HuSignature™) helps to identify predictive biomarkers (HuTrial™), which can be used to predict success in the clinic and guide development using the signature derived companion diagnostics.
For more information about how Crown is employing image-guided micro-irradiation in conjunction with immunotherapy, visit www.crownbio.com.
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visitwww.crownbio.com.
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Crown Bioscience Appoints John Gu as Chief Executive Officer
Crown Bioscience appoints John Gu as CEO, leveraging his expertise in AI-driven drug discovery to advance biotechnological innovation and global health.
Crown Bioscience Completes Merger with Indivumed Services
Crown Bioscience completes Indivumed Services merger, offering enhanced drug development solutions globally and retiring the Indivumed brand.
Crown Bioscience Germany GmbH Achieves Continued CAP 15189:2022 Accreditation
Crown Bioscience's Hamburg site secures continued CAP ISO 15189:2022 accreditation, showcasing its commitment to quality in laboratory services.
Crown Bioscience Wins 2024 Fierce CRO Award for Excellence in Client Service and Partnership
Crown Bioscience wins 2024 Fierce CRO Award for excellence in client service, underscoring its commitment to innovative drug development partnerships.
Crown Bioscience Wins BioTech Breakthrough Award for Drug Development Innovation
Crown Bioscience's OrganoidXplore receives BioTech Award, revolutionizing oncology with advanced preclinical screening.